ClinicalTrials.gg
CompletedNCT07877129Updated Oct 16, 2026

Exploring the Exercise Fear Experiences of Patients With Peripheral Arterial Disease: A Qualitative Study

An observational study in Peripheral Arterial Disease, sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Observational

Updated Oct 16, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Other
Time perspective
Other
Enrollment
18
Sex
All
01

Study summary

This study explored the exercise fear experience of patients with lower extremity arteriosclerosis obliterans. We conducted qualitative interviews and identified four core themes contributing to patients' fear of physical activity, including physical discomfort, negative psychological feelings, biased cognition, and inadequate social and medical support. The findings explained how exercise fear gradually develops and forms a vicious cycle of activity avoidance. Based on patients' real experience, we proposed a targeted exercise support framework. This research helps clinical staff better understand patients' inner barriers to exercise, carry out individualized psychological and rehabilitation interventions, improve patients' exercise adherence, and promote long-term disease rehabilitation.

02

Conditions studied

  • Peripheral Arterial Disease

Keywords

  • Peripheral arterial disease, Exercise fear, Kinesiophobia, Qualitative study, Fear- Avoidance Model, Exercise adherence
03

In context

Peripheral Arterial Disease

1,573 studies on the registry are indexed under Peripheral Arterial Disease; 284 are open to participants now.

This study's enrollment of 18 is below the median of 190 across 427 observational studies indexed under Peripheral Arterial Disease.

Browse Peripheral Arterial Disease studies →

Lead sponsor

The Fourth Affiliated Hospital of Zhejiang University School of Medicine is the lead sponsor of 92 studies on the registry; 78 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Peripheral arterial disease (PAD), wihch often presents clinically as lower extremity arteriosclerosis obliterans, has become a major global public health concern. Its prevalence is estimated to exceed 236 million cases worldwide[1]. The condition is characterized by chronic lower limb ischemia and the debilitating symptom of intermittent claudication, placing a significant burden on healthcare systems and reducing patients' quality of life.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meets the diagnostic criteria of PAD[3], (2) Age≥18 years, (3) The score on the Kinesiophobia Rating Scale > 37 points[17],(4) Clear consciousness and able to accurately express their viewpoints.

Exclusion criteria

Exclusion Criteria:

  • (1)severe comorbidities that independently restrict walking ability, such as advanced osteoarthritis, uncompensated heart failure, or severe chronic obstructive pulmonary disease; (2) cognitive impairment, dementia, or severe psychiatric disorders.
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
18 participants (actual)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • PAD

    Peripheral arterial disease (PAD), wihch often presents clinically as lower extremity arteriosclerosis obliterans, has become a major global public health concern. Its prevalence is estimated to exceed 236 million cases worldwide

    Other: a descriptive qualitative design

Interventions

  • Othera descriptive qualitative design

    The finalized formal interview outline included the following questions: (1) What do you think about exercise and rehabilitation in daily life? (2) Could you tell me about your experiences with physical activities or exercise since your diagnosis? (3) How has exercise fear changed your daily exercise behavior? (4) What impact do you think exercise fear has had on your life? (5) How do you cope with the experience of exercise fear?(6) In response to the current situation, what kind of support do you hope to receive during the exercise rehabilitation?

06

What researchers measure

Primary outcomes

  1. TSK(Tampa Scale for Kinesiophobia)

    TSK measure the extent of fear in PAD populations

    Time frame: 2026.01-2026.04

07

Study locations

1 site
  • Descriptive Qualitative Study
    Yiwu, China
08

References and documents

Publications

  • Deng L, Du C, Liu L, Wang Y, Gu H, Armstrong DG, Mills JL, Hochlenert D, Deng H, Ran J, Chen Y, Jiang X, Ma Y, Chen Q, Deng W; "Flow and Toe" Research Team (FORT)double dagger. Forecasting the Global Burden of Peripheral Artery Disease from 2021 to 2050: A Population-Based Study. Research (Wash D C). 2025 Jul 1;8:0702. doi: 10.34133/research.0702. eCollection 2025. PubMed 40599301 ↗
  • Yan C, Chen J, Xu X, Wei H, Li J. Global burden of peripheral arterial disease (1990-2021), global burden trends and the impact of blood lead on peripheral arterial disease: a multidimensional analysis based on NHANES, GBD, and Mendelian randomization. J Transl Med. 2025 Apr 23;23(1):463. doi: 10.1186/s12967-025-06408-3. PubMed 40269919 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07877129
Lead sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Responsible party
Sponsor
First posted
Oct 16, 2026
Start date
Jan 1, 2026
Primary completion
Apr 30, 2026
Completion
Apr 30, 2026
Last update
Oct 16, 2026

Study contacts

Xiaodan Zhu, bachelor
principal investigator · The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Xiaodan Zhu, bachelor
study director · The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion